{"ok":true,"nota":{"id":"765250b9cee6797d","slug":"una-variante-genetica-que-reduce-la-inflamacion-protege-de-infartos-y--765250","titulo":"Una variante genética que reduce la inflamación protege de infartos y aneurismas en ratones","resumen":"Modificaron ratones para reproducir una variante humana del gen IL6RA asociada a menor riesgo cardiovascular. Los animales desarrollaron menos aterosclerosis y aneurismas de aorta abdominal que los del grupo de control.","fuente":"biorxiv","fuenteNombre":"bioRxiv · preprints","color":"#be2628","autor":"Takaoka, M., Sharma, R., Lareyre, F., Clement, M., Harrison, J., Masters, L., Lu, Y., Paul, D., Mallat, Z.","url":"https://www.biorxiv.org/content/10.64898/2026.10.16.759391v1?rss=1","imagen":"/hoy/portada/765250b9cee6797d","tema":"salud","subtemas":["enfermedad cardiovascular","aterosclerosis","inflamación","aneurisma aórtico"],"entidades":["bioRxiv","IL6RA","ziltivekimab"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-21T00:00:00.000Z","indexTs":"2026-10-22T04:37:56.220Z","hash":"8792130030e2b89331587826ff80e8f5ad026e5e2eafe8d147da6ac4db4a7b05","tsa":{"time":"Oct 22 04:38:22 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Hace poco un fármaco que bloqueaba la IL-6 no redujo eventos cardiovasculares en pacientes, y esto puso en duda el papel de esa vía. Este trabajo sugiere que la forma de bloquearla importa tanto como el hecho de bloquearla. Para la gente de acá, con alta incidencia de enfermedades del corazón, la pregunta de qué terapia realmente sirve sigue abierta, y el resultado es sólo en ratones.","quienFirma":"bioRxiv (preprint de investigadores internacionales)","confianza":"preprint","consulta":null},"sello":{"hash":"8792130030e2b89331587826ff80e8f5ad026e5e2eafe8d147da6ac4db4a7b05","sello":"e6d74a2eccf37b508f477ce085e3ca14119ed4cdc4031b965ff4b7ecac60c50e","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6573762,"aleatorio":"2bf3d68605c0cf93c7b24bcf7d4852029c1a8fd2dd29c3bf1b3b697bee72ee36","tiempo":"2026-10-22T04:38:00.000Z"},"nist":{"cadena":2,"pulso":1994086,"salida":"7C444532759162AF322A7FA62FB67EDB4DE6FC6E7A6186DDCB567613FCA6BF322E4D0A282AEEE85DC1460DE99BE46FB63B8A2617A10BE805A6618E195E0116AC","tiempo":"2026-10-22T04:37:00.000Z"},"noAntes":"2026-10-22T04:38:00.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 22 04:38:22 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Modelling the human IL6RA Asp358Ala variant in mice: effects on atherosclerosis and abdominal aortic aneurysm","descripcion":"The association of IL6RA Asp358Ala variant with reduced risk of atherosclerotic cardiovascular disease (ASCVD) and abdominal aortic aneurysm (AAA) prompted interest in targeting IL6 signalling in these conditions. A recent report that ziltivekimab, a neutralising anti-IL6 antibody, did not reduce major adverse cardiovascular events in patients with ASCVD and chronic kidney disease, has cast doubt on the causal role of IL6 signalling in ASCVD. Here, we show that introducing the orthologous IL6RA Glu357Ala substitution in male mice leads to the same alteration in soluble IL6RA levels seen in humans, and significantly prevents atherosclerosis and AAA. Thus, therapies that more closely reproduce","pubDate":"2026-10-21","url":"https://www.biorxiv.org/content/10.64898/2026.10.16.759391v1?rss=1"},"indexado":"2026-10-22T04:37:56.220Z"}}